The launch of a new product typically has a positive impact on a company's stock as it can lead to increased sales and revenue. In this case, the QuantiFERON-EBV RUO Assay is designed to support research into EBV infection and related malignancies, which could potentially increase QIAGEN's market share in the biotech sector.